Key terms
About VIGL
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VIGL news
Yesterday
12:25am ET
Vigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker Breakthroughs
Apr 17
4:15pm ET
Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
Mar 29
4:27am ET
Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts
Mar 26
1:05pm ET
Buy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial Position
Mar 20
7:17am ET
Vigil Neuroscience appoints Kaufmann as Chief Medical Officer
Feb 09
8:29am ET
Stifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)
Feb 08
8:15am ET
Acrivon Therapeutics appoints Magovcevic to board of directors
No recent press releases are available for VIGL
VIGL Financials
Key terms
Ad Feedback
VIGL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VIGL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
